Mar 3, 2015 8:00am EST Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Mar 2, 2015 8:40am EST Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum
Feb 9, 2015 1:45pm EST Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
Jan 15, 2015 7:00am EST Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
Jan 14, 2015 8:40am EST Tonix Pharmaceuticals to Present at the Noble Financial Annual Investor Conference
Jan 9, 2015 7:00am EST Tonix Pharmaceuticals Announces Clinical Progress on Potential Treatment for Headache
Jan 6, 2015 7:00am EST Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia
